SDSUV Result 2017

Tyme Technologies trades as part of the healthcare sector and is part of the biotechnology industry. Tyme Technologies Inc is a clinical-stage pharmaceutical company focused on discovering and developing targeted cancer therapeutics for a broad range of oncology indications. The Company is developing proprietary combination drug product.

Previous Intraday Performance:

The TYME shares had a previous change of -6.17% which opened at 1.58 and closed at 1.52. It moved to an intraday high of 1.61 and a low of 1.51.

SeekingAlpha:  Tyme Tech down 20% on pricing registered offering

Historical Performance:

Over the last five trading days, TYME shares returned -13.64% and in the past 30 trading days it returned -26.92%. Over three months, it changed -36.93%. In one year it has changed -30.59% and within that year its 52-week high was 4.64 and its 52-week low was 1.51. TYME stock is 0.66% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.62 and a 50 day moving average of 2.28. Right now, TYME stock is trading -41.92% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  AZN and SGH among premarket losers


The company has a market cap of $170.2m with 111.9m shares outstanding and a float of 58.9m shares. Trading volume was 545,065 shares and has experienced an average volume of 418,627 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Tyme Technologies was -0.21 which ended on 31st of March 2018.

The next earnings report will be: 05-10-2019

The long-term trend of the EPS is an important number as it indicates the present value of Tyme Technologies.

Indicators Also to Watch:

Based on the latest filings, there is 27.70% of institutional ownership.

I calculated the beta to be -76.29

SeekingAlpha:  AZN and SGH among premarket losers

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -223.76%, return on assets is -173.27% and price-to-book is 11.54.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here